Skip to content

AGI Seminar: Human iPSC-derived 3D Retinal Tissue

The National Eye Institute (NEI) invites you to “Human iPSC-derived 3D retinal tissue for stem cell-based therapies for retinal degenerative diseases” by Dr. Valeria Canto-Soler, as part of the Audacious Goals Initiative (AGI) Seminar Series in Neuroregeneration. 

The AGI for Regenerative Medicine in Vision is a strategic endeavor by NEI to expand support aimed at new treatments for vision disorders. By facilitating cross-disciplinary research, the AGI is tackling devastating and difficult-to-treat eye diseases.

Friday, November 19, 2021 from 1:00-2:00p ET

Use the following link to view this seminar:

This talk is open to the public, so please feel free to share this information. For additional assistance, please contact


Valeria Canto-Soler, Ph.D.

Dr. Canto-Soler completed her Ph.D. in Biomedical Sciences at Austral University in Argentina and a postdoctoral fellowship at the Wilmer Eye Institute, Johns Hopkins University. She joined the Wilmer faculty as a research associate in 2006 and was promoted to assistant professor in 2008. In July 2017 she joined the Department of Ophthalmology at the University of Colorado School of Medicine as the Doni Solich Family Chair in Ocular Stem Cell Research and the Director of CellSight – the Ocular Stem Cell and Regeneration Research Program. Over the years she has received several national and international awards including the POEN Award for Best Research Study in Ophthalmology, the Alcon Research Institute Young Investigator Award, and the William & Mary Greve Special Scholar Award from Research to Prevent Blindness. She has also been named Outstanding Personality by the Council of the Autonomous City of Buenos Aires, Argentina, in recognition to her scientific contributions.

Using human induced pluripotent stem cells (hiPSC), Dr. Canto-Soler and her research team established a method that led for the first time to the generation of light-sensitive miniature human retinas in a laboratory dish. At CellSight, Dr. Canto-Soler and colleagues are currently using this breakthrough technology to develop novel stem cell-based therapeutics to save and restore sight in patients with blinding diseases.


Amberlynn Reed
NEI Office of Regenerative Medicine

Closed captioning is available for this event. If you require any other services, please contact the NEI Office of Regenerative Medicine at at least 24 hours prior to the event.

Last updated: October 7, 2021